Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatm... SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0879 | -8.45192307692 | 1.04 | 1.06 | 0.97 | 48315 | 1.01311463 | CS |
| 4 | -0.0679 | -6.6568627451 | 1.02 | 1.15 | 0.8227 | 133503 | 0.97768765 | CS |
| 12 | -0.4439 | -31.7979942693 | 1.396 | 1.42 | 0.8227 | 159957 | 1.08561847 | CS |
| 26 | -0.5579 | -36.9470198675 | 1.51 | 1.62 | 0.8227 | 179486 | 1.19973475 | CS |
| 52 | -0.5679 | -37.3618421053 | 1.52 | 3.07 | 0.8227 | 185451 | 1.59148072 | CS |
| 156 | -3.0479 | -76.1975 | 4 | 4.04 | 0.8227 | 345817 | 2.4281101 | CS |
| 260 | 0.1616 | 20.4427577483 | 0.7905 | 11.3 | 0.6018 | 387901 | 3.68091119 | CS |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
